This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
As outlined in our original report, the ACMD recognise the indisputable harms associated with taking GBL and 1,4-BD, both of which are rapidly converted to gamma-hydroxybutyrate (GHB) when ingested. GHB (but not GBL and 1,4-BD) was controlled as a Class C drug on 1st July 2003, under the Misuse of Drugs Act 1971. Our report was initiated by concerns that users of GHB may have switched to using GBL and 1,4-BD.